# Non-inferiority of Pharmacological Prevention Alone Versus Pancreatic Stents to Prevent Post-ERCP Pancreatitis

> **NCT02368795** · NA · UNKNOWN · sponsor: **Tehran University of Medical Sciences** · enrollment: 400 (estimated)

## Conditions studied

- Pancreatitis

## Interventions

- **DEVICE:** Pancreatic Stent
- **DRUG:** Indomethacin
- **DRUG:** Isosorbide Dinitrate
- **DRUG:** Ringer's lactate

## Key facts

- **NCT ID:** NCT02368795
- **Lead sponsor:** Tehran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2017-01
- **Final completion:** —
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2015-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02368795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02368795, "Non-inferiority of Pharmacological Prevention Alone Versus Pancreatic Stents to Prevent Post-ERCP Pancreatitis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02368795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*